Reply to: “Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?”

We thank Riveiro-Barciela et al. for their interest in our paper “Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors”.1 They reported the case of a patient who developed grade 2 hepatitis under first line treatment with nivolumab (anti-PD-1) and dioxygenasel inhibitor for a metastatic melanoma. The hepatitis im proved with corticosteroid therapy. Because of tumor progression a second line treatment with ipilimumab (anti-CTLA4) was administered. She developed fulminant hepatitis induced by ipilimumab and she was treated with corticosteroids and mycophenolate mofetil, since no improvement was seen she underw ent plasma exchange with hepatitis resolution.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research